Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023
July 11 2023 - 4:05PM
Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical
company revolutionizing the delivery of therapies to the back of
the eye through the suprachoroidal space (SCS®), announced today
that George Lasezkay, Pharm.D., J.D., Clearside’s President and
Chief Executive Officer, will present at the SHARE™ Series
Monday Management Update for investors on Monday, July 17, 2023, at
11:30 am ET.
This virtual event combines a brief corporate
overview with a moderated fireside chat and provides access to
individual and institutional investors who will have the
opportunity to submit questions during the live session.
A link to the live and archived webcast may be
accessed on the Clearside website under the Investors
section: Events and Presentations.
About Clearside Biomedical,
Inc.
Clearside Biomedical, Inc. is a
biopharmaceutical company revolutionizing the delivery of therapies
to the back of the eye through the suprachoroidal space (SCS®).
Clearside’s SCS injection platform, utilizing the Company’s
patented SCS Microinjector®, enables an in-office, repeatable,
non-surgical procedure for the targeted and compartmentalized
delivery of a wide variety of therapies to the macula, retina, or
choroid to potentially preserve and improve vision in patients with
sight-threatening eye diseases. Clearside is developing its own
pipeline of small molecule product candidates for administration
via its SCS Microinjector. The Company’s lead program, CLS-AX
(axitinib injectable suspension), for the treatment of neovascular
age-related macular degeneration (wet AMD), is in Phase 2b clinical
testing. Clearside developed and gained approval for its first
product, XIPERE® (triamcinolone acetonide injectable suspension)
for suprachoroidal use, which is available in the U.S. through a
commercial partner. Clearside also strategically partners its SCS
injection platform with companies utilizing other ophthalmic
therapeutic innovations. For more information, please visit
clearsidebio.com.
Source: Clearside Biomedical, Inc.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From Apr 2024 to May 2024
Clearside Biomedical (NASDAQ:CLSD)
Historical Stock Chart
From May 2023 to May 2024